SRPT — Sarepta Therapeutics, Inc.
$16.07
+$0.06 (+0.37%)
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene.
Market Cap
$1.72B
Forward P/E
10.8x
52-Week Range
N/A
SRPT Price History
Revenue vs. Net Income
$2.2B
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
-$315M
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
-29.5%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
1.5x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
5.0%
CapEx · FY2025
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
-7.2%
Net buyback · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
